Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025)
Authors:
Open Access
- 16 April 2026
- journal article
- review article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (4) , e71353
Abstract
Alzheimer's disease (AD) continues to pose a major public health challenge. Since its launch in 2004, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has played a pivotal role in advancing the field by providing a comprehensive, open‐access, longitudinal dataset that integrates neuroimaging, biomarker, genetic, and clinical data related to AD. We used standard literature search methods to identify ∼1830 publications from 2023 to mid‐2025 that used ADNI data or samples. This review highlights key ADNI studies with direct clinical applications. We describe how these have impacted the development and validation of plasma biomarkers, improved clinical trials, assessed AD therapies, and developed methods for diagnosis and prediction using clinical, fluid, and imaging biomarkers. These contributions are underlain by an improved understanding of biological mechanisms of disease progression in AD and highlight ADNI's central role in advancing translational research and accelerating progress toward more effective, individualized care for patients with AD.Keywords
Funding Information
- National Institute on Aging
- National Institutes of Health (U19 AG024904)
This publication has 116 references indexed in Scilit:
- Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s DiseaseCell, 2020
- Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging InitiativeMolecular Psychiatry, 2020
- Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging InitiativeAlzheimer's & Dementia, 2018
- Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndromeMolecular Neurodegeneration, 2017
- Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trialsAlzheimer's & Dementia, 2017
- A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkersNeurology, 2016
- Plasma β-amyloid in Alzheimer’s disease and vascular diseaseScientific Reports, 2016
- Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014Alzheimer's & Dementia, 2015
- The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PETAlzheimer's & Dementia, 2014
- The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inceptionAlzheimer's & Dementia, 2011